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Abstract
Background: Kawasaki disease (KD) is an acute systemic vasculitis of small and middle size arteries; 15-25 % of
untreated patients and 5 % of patients treated with intravenous immunoglobulin (IVIG) develop coronary artery
lesions (CAL). Many studies tried to find the most effective treatment in the management of resistant KD and to
select the risk factors for CAL.
Our data are assessed on children from west Sicily, characterized by a genetic heterogeneity.
Methods: We studied the clinical data of 70 KD Sicilian children (36 males: 51 %; 34 females: 49 %), analysed
retrospectively, including: demographic and laboratory parameters; echocardiographic findings at diagnosis, at 2, 6
and 8 weeks, and at 1 year after the onset of the illness.
Results: Forty-seven had Typical KD, three Atypical KD and twenty Incomplete KD. Age at the disease onset ranged
from 0.1 to 8.9 years. IVIG were administered 5 ± 2 days after the fever started. Defervescence occurred 39 ± 26
hours after the first IVIG infusion. Fifty-six patients (80 %) received 1 dose of IVIG (responders); 14 patients (20 %)
had a resistant KD, with persistent fever after the first IVIG dose (non responders). Ten (14 %) non responders
responded to the second dose, 4 (5 %) responded to three doses; one needed treatment with high doses of
steroids and Infliximab.
Cardiac involvement was documented in twenty-two cases (eighteen with transient dilatation/ectasia, fifteen with
aneurysms). Pericardial effusion, documented in eleven, was associated with coronaritis and aneurysms, and was
present earlier than coronary involvement in seven.
Hypoalbuminemia, D-dimer pre-IVIG, gamma-GT pre-IVIG showed a statistically significant direct correlation with
IVIG doses, highlighting the role of these parameters as predictor markers of refractory disease. The persistence of
elevated CRP, AST, ALT levels, a persistent hyponatremia and hypoalbuminemia after IVIG therapy, also had a
statistical significant correlation with IVIG doses.
Non responders showed higher levels of D-dimer and gamma-GT pre-IVIG, persistent high levels of D-dimer, CRP,
AST, ALT, hypoalbuminemia and hyponatremia after IVIG.
Conclusions: This is the first study on KD in Sicily. We suggest some laboratory parameters as predictive criteria for
resistant KD. Patients who show early pericarditis need careful surveillance for coronary lesions.
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Background
Kawasaki disease (KD) is an acute systemic vasculitis, af-
fecting small and middle size arteries, occurring mainly
in infants and children up to 5 years of age [1, 2]. It is
the second most common cause of vasculitis after
Schönlein-Henoch Purpura and the first cause of ac-
quired heart disease in childhood in western countries
[3]. It is self-limited, with fever resolving after an average
of 12 days even without treatment [1], of unknown aeti-
ology and is characterized by a marked increase of
serum levels of proinflammatory cytokines and chemo-
kines [1] and the activation of the innate and adaptive
immune system [4–6].
Timely administration of IVIG is fundamental to re-
duce inflammation of coronary artery walls and to pre-
vent coronary damage; the long-term treatment in
individuals developing coronary aneurysms must prevent
myocardial ischemia and infarction [1]. About 15-25 %
of untreated KD patients and approximately 5% KD pa-
tients who received intravenous immunoglobulin (IVIG)
treatment may develop coronary artery lesions (CAL).
IVIG administered 10 days or more after fever on-
set may contribute to reduce inflammation but are
usually thought to be ineffective in preventing CAL
[7]. The rate of IVIG resistance is higher in patients
treated before the fifth day of fever, though it is un-
clear whether a poor outcome follows the early treat-
ment or if patients diagnosed with KD before the
fifth day have a more severe form of the disease with
a higher risk of cardiac lesions [8].
A single high dose of IVIG (2 g/kg), combined with
acetylsalicylic acid, is the gold standard therapy in the
acute stage of KD. However, approximately 8-38 % of
children are unresponsive to initial high dose IVIG treat-
ment and this condition is defined as “refractory KD”.
These patients have an increased risk of CAL
development.
Many authors tried to define risk factors of IVIG
failure. Kuo et al. showed that pre-IVIG hypoalbumin-
emia (≤2.9 g/dL) was more common in non re-
sponders to IVIG than in good responders [9].
Kobayashi et al. defined a score system to calculate
the risk of refractory KD. They indentified seven vari-
ables to generate a scoring model useful to predict
IVIG resistance: days of illness at initial treatment ≤ 4,
age ≤ 12 months at the onset, high serum levels of
AST ≥100 IU/L, high CRP (≥10 mg/dl), elevated per-
centage of neutrophils (≥80 %), low serum sodium
levels (≤133 mmol/L), low platelet count (≤30.0 × 104/
mm3) [10]. Other authors included a lower lympho-
cytes count in the Kobayashi score to increase the
predictive value of IVIG-resistant patients during the
subacute phase [11]. However the score has not per-
formed well in non-Japanese populations [12].
Failure of the first dose of IVIG remains the most sig-
nificant risk factor for CAL. However, there are few
studies on non-responders to a second dose of IVIG. A
recent study reported that patients with CRP level ≥
8mg/dl after the first dose of IVIG, have a higher risk to
fail additional IVIG doses and may require further IVIG
plus rescue therapy [13]. Furthermore these patients
have a higher incidence of CAL with persistent lesions
[13]. Other authors have recently evidenced that ele-
vated D-dimer levels are a risk factor for CAL in patients
non responder to IVIG treatment [14]. Recently, frac-
tional change-C-reactive protein was also considered to
be useful for predicting initial IVIG resistance in KD
[15]. Refractory KD may require additional therapy such
as a second dose of IVIG, steroids, infliximab or other
biological drugs. As for corticosteroids, Ogata et al. eval-
uated the efficacy of steroids plus IVIG treatment for
KD defined at high risk. Intravenous methylprednisolone
at the dose of 30 mg/kg for three days in association
with IVIG was effective to guarantee a good response
and prevent CAL [16].
We aimed to describe clinical characteristics and se-
verity factors in KD patients in Sicily and to analyze the
risk factors of severe and/or refractory form of KD. Sicil-
ian Caucasian population had origin from a miscellan-
eous of many populations coming from Greece, Northen
Europe, Arabic countries, Spain, France, Northen Italy…
They conquered this country in the course of the cen-
turies, with complex cultural, familial and genetic inter-
actions. These people married with local people,
acquired local customs and traditions and several times
maintained their residence in Sicily.
To our knowledge this is the first KD study in the
island.
Methods
Patients
We analyzed the clinical data of 70 KD Sicilian children,
admitted to the Paediatric Clinic of Palermo from 2008
to 2014.
Charts were analyzed retrospectively and data were
collected in a customized database. Data included demo-
graphic and laboratory parameters (age, sex, days of
fever at the admittance, days of fever at the start of
IVIG, neutrophils, lymphocytes and platelet count,
haemoglobin, albumin, ALT, AST, gamma-GT, C-
reactive protein (CRP), erythrocyte sedimentation rate
(ESR), Na, D-dimer), as well as echocardiographic find-
ings at diagnosis, at 2 weeks, at 6 to 8 weeks, and at 1
year after the onset of the illness.
More frequent echocardiographic evaluation was per-
formed only in patients at high risk (children persistently
febrile or with CAL, ventricular dysfunction, pericardial
effusion, or valvular regurgitation).
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The study has been granted from requiring ethics ap-
proval by the ethics committee. “Comitato Etico
Palermo1”.
Ethics committee approval was not necessary since for
anonymized data this is not required by Italian
regulations.
In order to early identify non responders, after con-
sidering the Kobayashi score system and other side
factors considered in the international literature, we
analyzed the following parameters: age, gender, days
of the disease at IVIG start, neutrophils, lymphocytes
and platelet count, haemoglobin, albumin, ALT, AST,
gamma-GT, CRP, ESR, Na, D-Dimer. We correlated
these parameters to each other and with the days of
fever at the start of the IVIG treatment, the response
to IVIG, the clinical and laboratory outcome, cardio-
logic involvement and CAL.
Statistics
All variables were tested for normality with the
Anderson-Darling normality test. All variables were
expressed as mean ± standard deviation. The degree of
linear relationship between clinical, microbiological
and biochemical parameters was calculated using
Pearson product moment correlation coefficient; stat-
istical significance was accepted at p less than 0.05.
Calculations were performed using MiniTAB release
13.1 Statistical Software.
Results
Among the 70 patients [Males: 36 (51%); Females: 34
(49%); age (mean ± SD): 2.17 ± 1.80 years] the male to fe-
male ratio of KD patients was 1:1. Forty-seven (68%)
were diagnosed as typical KD, 3 (4%) as atypical KD, 20
(28%) as incomplete KD, following the definition of
Committee on Rheumatic Fever, Endocarditis, and
Kawasaki Disease, Council on Cardiovascular Disease in
the Young, American Heart Association [1, 17].
At the hospitalization fever had been present for a
mean of 5 ± 2 days; the most frequent signs/symptoms
at diagnosis are described in Table 1. Associated findings
included radiographically confirmed pneumonia in 6 pa-
tients; hepatomegaly documented by ultrasound in 44
patients, and gallbladder enlargement in 35.
Echocardiographic follow up showed the persistence
of coronary lesions (varying from coronary brightness to
aneurysms), at 6 to 8 weeks, and at 1 year after the
onset of the illness in thirty-three patients (47 %): the z-
score was > 4 in 15/33 patients (45 %); > 2.5 and < 4 in
18/33 children (55 %). CAL were reported in 22/47 pa-
tients (47 %) with typical KD, 2/3 patients (67 %) with
atypical KD, 9/20 patients (45 %) with incomplete KD.
Among the patients who developed coronary involve-
ment, 25 (76 %) were responders, 8 (24 %) were non re-
sponders. Among the 15 patients (21 %) who developed
coronary aneurysms, 12 (80 %) had typical KD; one had
atypical KD; two had incomplete KD.
IVIG were administered 5.3 ± 2.4 days after the fever
started. Defervescence occurred 39 ± 26 hours after the
first IVIG infusion. Among the 70 patients, 56 patients
(80 %) received 1 dose of IVIG (responders); 14 patients
(20 %) had a resistant KD, with persistent fever after the
first IVIG dose (non responders). In the group of non
responders KD, 10 (14 %) responded to the second dose,
4 (5 %) responded to three doses while only one patient
needed treatment with high doses of steroids and
Infliximab.
Seventy-one percent (10/14) of non-responders vs 50
% (28/56) of responders showed cardiac involvement (p
< 0.05). Pericarditis was present in eleven and associated
with coronaritis in 7/25 (28%), with aneurysms in 5/15
(33 %), and in seven it was documented earlier than cor-
onary involvement. The evidence of early pericarditis
had a significant positive correlation with the develop-
ment of aneurisms (p = 0.035; r = 0.253).
Acquired valvular insufficiency (of tricuspid and/or
mitral valves) was documented in 4 patients, all in the
non responder group. Valvular insufficiency had a statis-
tically significant positive correlation with the doses of
IVIG (p = 0.002; r = 0.358) and fibrinogen pre-IVIG (p =
0.048; r = 0.273).
Among the 15 patients who developed coronary aneu-
rysms, 11 (73 %) were responders, 4 (27 %) were non re-
sponders: these received three IVIG doses.
The presence of coronary aneurysms showed a sta-
tistically significant positive correlation with IVIG
doses (p = 0.026; r = 0.265), with platelet count pre-
IVIG (p = 0.045; r = -0.240), AST and ALT post-IVIG
(p = 0.002; r = 0.364 and p = 0.001; r = 0.390), gamma-GT
post-IVIG (p = 0.030; r = 0.290), D-dimer post-IVIG
(p = 0.023; r = 0.379).
The significant differences between responders and
non responders are shown in Table 2.
Furthermore in the non responder group, 7 (50 %)
were males, and 3/7 (43%) did not respond to the sec-
ond dose of IVIG and received 3 doses of IVIG; 7 non
responders (50 %) were females, and only one of them
(14 %) did not respond to the second IVIG dose.
Table 1 Signs/Symptoms at diagnosis
Symptoms Number of patients Percentage (%)
Fever 70 100
Conjunctivitis 62 86
Stomatitis 59 84
Rash 50 71
Lymphadenopathy 43 61
Extremity changes 7 10
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We applied the Kobayashi score to our patients and
verified that in IVIG non responder group the score
was ≥ 4 only in 8/14 patients (57 %). The Kobayashi
score was ≥ 4 in 8/15 (53 %) patients who developed cor-
onary artery aneurysms. In IVIG responders, the
Kobayashi score was ≥ 4 in 8/54 (15 %).
Natraemia and albuminemia pre-IVIG were lower in
non responders, however the correlation did not reach
the statistical significance. On the contrary, persistent
hyponatraemia and hypoalbuminemia after the first IVIG
dose had a significant correlation with the number of
IVIG doses, with a negative correlation of IVIG doses
with natraemia and albuminemia post-IVIG (p = 0.039;
r = -0.258 and p = 0.05; r = -0.243 respectively),
gamma-GT pre-IVIG (p = 0.014; r = -0.314), AST post-
IVIG (p = 0.016; r = -0.290), ALT post-IVIG (p = 0.000;
r = -0.468), low haemoglobin levels and platelet count
after the first dose of IVIG (p = 0.05; r = -0.236); it
showed a positive correlation with CRP levels post-IVIG
(p = 0.030; r = 0.263) and D-dimer pre-IVIG (p = 0.005; r
= 0.389),. However only 4/14 (29 %) in the non responder
group had low platelet count in acute phase (≤30.0 ×
104/mm3).
Coronary aneurysms showed a statistically significant
positive correlation with IVIG doses (p = 0.026; r = 0.265),
with platelet count pre-IVIG (p = 0.045; r = -0.240), AST
and ALT post-IVIG (p = 0.002; r = 0.364 and p = 0.001;
r = 0.390 respectively), gamma-GT post-IVIG (p = 0.030;
r = 0.290), D-dimer post-IVIG (p = 0.023; r = 0.379).
Furthermore valvular insufficiency had a significant
positive correlation with fibrinogen pre-IVIG (p = 0.048;
r = 0.273).
D-dimer had a statistically significant correlation
with several laboratory parameters. D-dimer post-
IVIG had a statistically significant negative correl-
ation with CRP post-IVIG (p = 0.003; r = -0.475), and
a positive correlation with leukocyte count post-IVIG
(p = 0.004; r = 0.469) and with the percentage of neu-
trophils post-IVIG (p = 0.002; r = 0.493). Fibrinogen
pre-IVIG had a statistically significant positive correlation
with leukocytes pre-IVIG (p = 0.002; r = 0.453) and
with the percentage of neutrophils pre-IVIG (p = 0.000;
r = 0.496).
Discussion
The aetiology of KD remains unknown; however, epide-
miologic evidence suggests the possible role of infectious
agents in patients with a genetic background [18]. The
incidence of cardiac involvement varies between differ-
ent studies; however, it is higher in patients with refrac-
tory KD and in untreated patients (25%) [19]. In our
population coronary artery aneurysms were present in
21% of patients: the majority of them were patients with
typical KD. Cardiac involvement was present in 71% of
non responders vs. 50% of responders, in accordance
with published data [1, 3, 14].
A recent report described patients with precocious
pericardial effusion and later development of CAL [20].
In our patients pericardial effusion was associated with
coronaritis in 28 %, associated with aneurysms in 33%,
and was documented earlier than coronary involvement,
confirming previous findings.
Hepatomegaly and gallbladder enlargement were signs
documented by ultrasound in 63 % and 50 % of patients,
respectively. The high incidence of these complications
may be explained by the routine abdominal ultrasound
performed in these patients, at diagnosis and during per-
sistence of fever and/or of increased biochemical signs
of inflammation.
We tested the ability of the Kobayashi Score [10] to
predict IVIG resistance and coronary artery aneurysms
in our patients; however these conditions were not pre-
dicted by a high Kobayashi Score, because about 50 % of
the patients were missed by the score. Other authors
tested this and other scores in their populations, but did
not demonstrate a diagnostic utility [21–24].
In our patients hypoalbuminemia, D-dimer levels pre-
IVIG and gamma-GT pre-IVIG showed a statistically
significant direct correlation with IVIG doses, highlight-
ing the role of these parameters as possible predictors of
refractory KD. Furthermore, patients who show early
pericarditis need more careful surveillance for CAL [20]
with regard to treatment [25].
In a recent wide-scale study performed in Japan, age,
sex, CRP levels, platelet count, lower albumin levels were
confirmed to be linked to a higher risk of CAL [26]. In
our population coronary aneurisms showed a statistically
Table 2 Clinical features and laboratory findings in responders and non responders patients
Responders Non responders P
Cardiac involvement 50 % (28/56) 71 % (10/14) p < 0.05
Age 2.34 ± 1.92 years 2.17 ± 1.80 years p = NS
First dose of IVIG < 5 days 5/56 (9 %) 4/14 (29 %) p < 0.05
Hyponatraemia (< 133 mEq/L) 23/56 (41 %) 11/14 ( 79 %) p < 0.05
D-dimer (ng/ml) pre-IVIG 818 ± 666 1342 ± 898 p < 0.05
D-dimer (ng/ml) post-IVIG 635 ± 545 1073 ± 1011 p < 0.05
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significant correlation with IVIG doses, platelet count pre-
IVIG; AST, ALT, gamma-GT post-IVIG; D-dimer post-
IVIG. These data confirm a link between coronary vascu-
litis and the severity of systemic vascular inflammation
and/or extra-cardiac involvement.
Our center is one of the three major pediatric hospitals
in Sicily were children affected by Kawasaki disease are
treated. However we have not yet the epidemiological data
about the real incidence of Kawasaki disease in our region.
A recent study evaluated epidemiology of KD in cen-
tral Italy: the peak of incidence was in the second year
of life, with a mild prevalence of males. The icidence
was 17.6:100.000 children under five years. 5.2 % had
one or more cardiac complications, 2.6 % had CAL [27].
Conclusion
In conclusion, this is the first study on KD in Sicily: we
described the clinical data and evaluated the correlation
of clinical and biochemical data with the response to
IVIG in a genetically heterogeneous population. History
reveals that Sicily was the theatre of different domina-
tions (from Phoenicians to Greeks, Romans, Arabs,
Normans, Bourbons): these populations leaved in the
island art, culture and a complex genetic imprinting whose
influence is still alive.
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